LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Home・Akcijų sąrašas・Sana Biotechnology Inc

Sana Biotechnology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.68 -3.6

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.66

Max

2.84

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-17M -59M
Darbuotojai	142
EBITDA	-11M -50M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+242.96% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-273M 833M
Ankstesnė atidarymo kaina	6.28
Ankstesnė uždarymo kaina	2.68

Naujienos nuotaikos

By Acuity

50%

169 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

1.68 / 1.87 Palaikymas ir pasipriešinimas

Sana Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-30 23:15; UTC

Svarbiausios naujienos

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

2026-03-30 22:36; UTC

Svarbiausios naujienos

Australian Government Rules Out Boots on the Ground in the Middle East

2026-03-30 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

2026-03-30 21:00; UTC

Uždarbis

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

2026-03-30 20:15; UTC

Svarbiausios naujienos

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

2026-03-30 23:40; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-30 23:40; UTC

Rinkos pokalbiai

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

2026-03-30 23:36; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

2026-03-30 23:12; UTC

Rinkos pokalbiai

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

2026-03-30 22:49; UTC

Rinkos pokalbiai

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

2026-03-30 22:44; UTC

Rinkos pokalbiai

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

2026-03-30 22:43; UTC

Rinkos pokalbiai

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

2026-03-30 22:42; UTC

Rinkos pokalbiai

South32 Should Go for Growth, Says New Bull -- Market Talk

2026-03-30 22:18; UTC

Rinkos pokalbiai

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

2026-03-30 22:05; UTC

Rinkos pokalbiai

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

2026-03-30 21:58; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Financial Agrees to Buy Bell Partners for $350M

2026-03-30 21:39; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

2026-03-30 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

2026-03-30 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

2026-03-30 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

2026-03-30 21:25; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-30 21:25; UTC

Rinkos pokalbiai

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

2026-03-30 21:03; UTC

Įsigijimai, susijungimai, perėmimai

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

2026-03-30 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-03-30 20:09; UTC

Uždarbis

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

2026-03-30 20:00; UTC

Svarbiausios naujienos

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Akcijų palyginimas

Kainos pokytis

Sana Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

242.96% į viršų

12 mėnesių prognozė

Vidutinis 9.5 USD 242.96%

Aukščiausias 12 USD

Žemiausias 7 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sana Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Sana Biotechnology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.68 / 1.87Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Rinkos nuotaikos

By Acuity

169 / 349 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.